What? When? Why?
Latest Happenings in Business World
North America led the cell therapy market in 2021.
As per our research report, the global cell therapy market size is estimated to grow USD 42.37 billion by 2027 from USD 10.69 billion in 2022, rising at a CAGR of 31.7% from 2022 to 2027.
The cell therapy market is negatively affected by the pandemic as most countries have adopted strict measures to fight against the highly infectious pandemic across the globe. There have been numerous COVID-19 cases where the virus disproportionately affected people with underlying illnesses. These patients avoid most therapies to avoid severe complications due to their weak immune systems.
In addition, most clinics worldwide have restricted performing stem cell therapy in newly diagnosed cases with organ transplants and other treatments as they cannot overburden the current healthcare condition over the next few months. Furthermore, many biopharmaceutical companies have delayed several clinical trials for non-essential drugs while there have been extensive studies exploring treatment modalities for diagnosis and treatment for the COVID-19 virus. There has been a negative impact on people undergoing cell therapies due to the high susceptibility rate from other carrier people. Additionally, due to social distancing restrictions, donors were less likely to donate their cells and were often unable to do so. This results in delays in harvesting cells that propagate through the cell therapy process, which has severely reduced the number of transplant surgeries across the globe. However, during early 2021, most countries have adapted their healthcare systems to tackle the pandemic and resume routine medical activities. This will help the cell therapy market resume normalcy over the analysis period.
The increase in the adoption of cell therapy research as a primary treatment modality or as an adjunct, technological advances in stem cell therapy, and the increase in the incidence of cancer, genetic disorders, and abnormalities are driving the market growth to new heights. Moreover, cell therapy has several applications in the development of regenerative medicine, which acts as a multidisciplinary field aimed at maintaining, improving, or restoring the function of cells, tissues, or organs.
Chronic diseases and conditions are on the rise, with many complications affecting patients’ daily lives. According to the International Diabetes Federation Diabetes Altas, in 2021, nearly 573 million adults worldwide were living with diabetes globally, with this figure expected to rise to 643 million by 2030 and 783 million by 2045. Often, the target population for cell therapies is the adult population, who are more prone to chronic diseases such as cancer, anemia, and Alzheimer's disease, among others. Advanced genomic analysis techniques, vast research data from cancer societies, and the proven efficacy of transplants are supporting the market. According to 2019 transplant statistics, approximately 18,000 people, ages 0 to 74, exposed to bone marrow or umbilical cord blood transplants have a higher success rate in the United States each year.
Several other factors such as increasing healthcare infrastructure, increased accessibility, growing awareness of cell therapy, and funds and investments to support new business launches are anticipated to drive organic growth in the market. The steady pace of innovative technologies will keep and help develop advanced therapies, which will contribute to the development of the cell therapy market. The introduction of several cell lines is considered the primary tool for building robust cellular data, which will help develop one single product.
On the contrary, the increasing number of strict regulations and high costs associated with cell therapy coupled with inadequate reimbursement policies are expected to have a negative impact on the global cell therapy market during the analysis period.
KEY MARKET INSIGHTS:
In 2021, the autologous segment dominated the global cell therapy market, with the largest share of over 53.28%. The segment is anticipated to maintain its dominance over the forecast period. Advantageous factors such as easy availability, no requirement to identify HLA-matched donors, low risk of life-threatening complications, no risk of GvHD, no need for immunosuppressive therapy favor the autologous segment over the allogenic segment. Moreover, autologous therapies are more affordable than allogeneic therapies, supporting this segment. However, the growth of cell banks and the relocation of companies to the development of allogeneic therapeutic products are driving the cell therapy market.
In 2021, the stem cells segment dominated the cell therapy market and will continue throughout the forecasted period. Factors such as supportive government initiatives, the increasing number of stem cell banks in developing countries, and growing awareness of stem cell banks positively impact the cell therapy market.
Autoimmune diseases, cancer, and other infectious diseases dominate the market with more than 40% share. Cell therapies have the potential growth to rebuild damaged cartilage in joints, repair spinal cord injuries, improve a weak immune system, and help patients with neurological disorders. All these applications have boosted the growth of the cell therapy market.
In 2021, the research institutes segment dominated the cell therapy market, with the largest share of over 60.9%. Studies associated with stem cells are mainly researched to explore the potential to replace, repair, regenerate damaged tissues, cells and organs. Currently, key players are investing heavily in developing effective and safer treatments as an alternative to traditional treatment modalities.
In 2021, North America held the largest market share, with 52.78%. This large share can be attributed to the presence of a considerable number of centers and institutes in the region, more focus on R&D related to stem cell activities the presence of skilled labor. In addition, increased developer and consumer investments in advanced cell therapy are estimated to increase revenue generated in this region.
Europe holds a significant share of the cell therapy market, with France and the UK being among the dominant regional markets. The increase in research and development activities in France, due to the presence of some of the leading research institutions in biotechnology and innovative cell therapies, is contributing to the market's growth. Meanwhile, the introduction of several favorable government initiatives to aid in research activities enhances the growth and thus contributes to the overall development of the market in the European region.
In Asia-Pacific, the cell therapy market will witness a lucrative growth rate of 15.52% during the aforementioned period owing to targeted R&D programs, a large patient population, and the growing popularity of medical tourism. Moreover, the presence of a flexible legal framework to promote stem cell therapy and increasing research funding in developing countries will provide lucrative opportunities for the market in the future.
Some of the major players in the cell therapy market include JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc. Anterogen Co., Ltd., Castle Creek Biosciences, Inc., Tameika Cell Technologies, Inc., The Future of Biotechnology, MEDIPOST Osiris Therapeutics, Inc. Pharmicell Co., Ltd, Cells for Cells, NuVasive, Inc. and Vericel Corporation.
SEGMENTS ANALYZED UNDER THIS REPORT:
By Cell Source:
Browse Regional Reports: